The Angiogenesis Group is part of the Oncology Area of the Biomedical Research Center of La Rioja (CIBIR), located in Logroño, Spain. As the name implies, the Angiogenesis Group focuses on the process of angiogenesis in relation to cancer and other relevant diseases in which hypoxia and pathological growth of blood vessels contribute to disease initiation and progression. The Group has contributed to the knowledge of a poorly understood family of angiogenic peptides, including adrenomedullin and the N-terminal 20 peptide of proadrenomedullin, through cellular and molecular biology as well as genetic (inducible Knock-out models) paradigms, characterizing their involvement in cancer and metastasis formation.

In addition, the Group is very interested in the discovery and application of biomarkers for the early detection of pancreatic cancer and holds several patents related to this topic. Due to its insidious nature, pancreatic cancer is often detected in advanced stages, which significantly reduces the chances of effective treatment. On the other hand, patients whose cancer is detected in early stages have a much higher chance of survival. Therefore, developing and validating a protocol for early detection represents today the best opportunity to increase survival among pancreatic cancer patients.